Atrys HealthXMAD:ATRY +0.79%66 3-Year ROIIC % is 1.48 as of Dec. 2025, which is 15% above its 10-year median of 1.29. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.13 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,324 Biotechnology companies, Atrys Health ranks better than 54.31% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Atrys Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1.48%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Atrys Health's 3-Year ROIIC % or its related term are showing as below:
XMAD:ATRY's 3-Year ROIIC % is ranked better than 54.31% of 1324
companies
in the Biotechnology industry
Industry Median: -4.42
vs XMAD:ATRY: 1.48
Atrys Health (XMAD:ATRY) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Atrys Health 3-Year ROIIC % Related Terms
Atrys Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Atrys Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Atrys Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Atrys Health's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Atrys Health (XMAD:ATRY) has a 3-Year ROIIC % of 1.48 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Atrys Health and its competitors. This is 15% above median its historical median of 1.29. According to the industry distribution chart, Atrys Health ranks #605 out of 1324 companies in the Biotechnology industry, placing it in the top 45.7%.
Is Atrys Health's 3-Year ROIIC % too high?
Atrys Health's current 3-Year ROIIC % of 1.48 is 15% above median its 10-year median of 1.29. Based on the distribution chart, Atrys Health ranks #605 out of 1324 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #605 out of 1324 companies for 3-Year ROIIC %. This puts Atrys Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Atrys Health and its competitors. Atrys Health's current 3-Year ROIIC % is 1.48, which is 15% above median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.13, compared to a current price of €2.54 — trading 18.8% below its estimated fair value. The current 3-Year ROIIC % is 1.48, which is 15% above median its 10-year median of 1.29. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current 3-Year ROIIC % is 1.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.54 is trading 18.8% below its estimated GF Value™ of €3.13.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
3-Year ROIIC %: 1.48 (15% above median its 10-year median of 1.29)
GF Value™: €3.13 vs. price of €2.54 (18.8% below fair value)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score
Get the complete analysis for XMAD:ATRY
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
